EVOQUE Transcatheter Tricuspid Valve Replacement Demonstrates Favorable Outcomes
The EVOQUE system has shown promising results in real-world outcomes for Transcatheter Tricuspid Valve Replacement (TTVR), confirming its safety, effectiveness, and quality-of-life gains.
According to the first U.S. real-world data from the STS/ACC TVT Registry, TTVR with the EVOQUE system achieved near-complete elimination of tricuspid regurgitation (TR), significant improvements in functional capacity and quality of life, and low complication rates at 30 days.
The results were presented by Dr. Rahul Sharma of Stanford University at the TCT Conference 2025 in San Francisco, USA. The registry analysis evaluated early commercial outcomes of the EVOQUE system, which is designed for patients with severe, symptomatic TR who are at high surgical risk.
Data were collected from 1,034 patients treated at 82 sites across the United States between February 2024 and March 2025.
No direct quote available in the given text.
Author's summary: EVOQUE system shows promising results in TTVR outcomes.
More News
- Lightning vs. Islanders Prediction, Odds, Picks - Dec. 6
- Kelly Massol : « J’ai réalisé 40% de mon ambition »
- Kelly Osbourne — Instagram Snapshot
- NBA: Spurs at Timberwolves
- Lando Norris wins his first F1 title despite Max Verstappen victory: Live updates and reaction
- Spurs' Kelly Olynyk: Ongoing Decline in Playing Time and Role
- JUST IN: Kelly Olynyk has been waived by the San Antonio Spurs
- How to watch Islanders vs. Lightning: TV channel and streaming options for December 6
- Jack Osbourne breaks silence on jungle feud with Kelly Brook
- Kelly Vedovelli révèle sa vie amoureuse